Aptose Biosciences Inc., of San Diego, said it priced its underwritten public offering of 16.125 million common shares at $4 each for gross proceeds of approximately $64.5 million. The underwriters have been granted a 30-day option to purchase up to an additional 2.41 million common shares. The company intends to use all or a portion of the net proceeds to accelerate and expand clinical trials for CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor in a phase I trial in patients with relapsed or refractory B-cell malignancies, and APTO-253 that directly targets the MYC oncogene and inhibits its expression.
Assembly Biosciences Inc., of South San Francisco, said it closed its underwritten public offering of 6.28 million shares at $16.50 each, which included the exercise in full by the underwriters of their option to purchase 1.13 million additional shares of common stock. The aggregate gross proceeds were approximately $143.7 million, and the company intends to use the net proceeds to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.
Bausch Health Companies Inc., of Laval, Quebec, said it has launched an offering of a combined $1.25 billion of new senior notes due 2028 and new senior notes due 2030. The company intends to use the proceeds from the offering to finance amounts owed under its putative securities class action Valeant Pharmaceuticals International Inc. Securities Litigation (filed in the U.S. District Court for the District of New Jersey). The litigation has been resolved with the company agreeing to pay $1.21 billion that includes a payment schedule with the first funding in mid-January 2020.
Cellestia Biotech AG, of Basel, Switzerland, said it closed a CHF 20 million (US$20.4 million) series B financing round. The company is progressing its clinical development program of CB-103, a first-in-class small-molecule targeted therapy with a novel mode of action. The compound is a highly selective protein-protein interaction inhibitor targeting an oncogene transcription factor for the precision medicine treatment of specific cancers.
Contrafect Corp., of Yonkers, N.Y., said it priced its underwritten public offering of 25.65 million shares at $0.39 each for gross proceeds of approximately $10 million. The company intends to use the net proceeds to fund initiation of its phase III DISRUPT trial of exebacase (CF-301) in S. aureus bacteremia, including right-sided endocarditis, to fund advancement of its portfolio, including IND-enabling activities for an engineered gram-negative lysin directly targeting highly-resistant Pseudomonas aeruginosa, and for working capital and other general corporate purposes.
Eyegate Pharmaceuticals Inc., of Waltham, Mass., said it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive top-line data on Nov. 22 for its pivotal corneal wound repair study. The company believes it will have sufficient cash to fund its planned operations through its process of evaluating several strategic options in order to determine the best path forward.
Forty Seven Inc., of Menlo Park, Calif., said it closed its public offering of 5.589 million shares of common stock, including 729,000 shares sold by the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds were approximately $195.6 million.
Immuneering Corp., of Cambridge, Mass., said it completed a $17 million series A financing and plans to use the proceeds to advance its lead program in cancer cachexia and its pipeline of oncology medicines driven by its Disease Cancelling technology. The company will also use proceeds to further develop its technology platforms, launch new drug programs in other disease areas and support the growth of its computational biology services business.
Innovative Cellular Therapeutics Inc., of Rockville, Md., said it closed a series B+ equity financing for an undisclosed amount led by LH Ventures. The proceeds will be used to advance ICTCAR-014, the company’s next generation CD19-targeting armored CAR T-cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells, into a U.S. clinical trial early next year, and to further develop its CAR T-cell therapy platform in solid tumors.
Nicox SA, of Sophia Antipolis, France, said it has drawn down the remaining €8 million (US$8.92 million) tranche of debt under its bond financing agreement with Kreos Capital. The company drew down an initial €8 million in January followed by an additional €4 million in October.
Triplet Therapeutics Inc., of Cambridge, Mass., said it launched with $59 million in financing including a $49 million series A round led by MPM Capital and Pfizer Ventures U.S. LLC. Atlas Venture, which co-founded and seeded Triplet with a $10 million investment, also participated in the round alongside Invus, Partners Innovation Fund and Alexandria Venture Investments. The company is focused on a transformative approach to developing treatments for repeat expansion disorders, a group of more than 40 known genetic diseases associated with expanded DNA nucleotide repeats. A significant body of human genetic evidence has identified that one central pathway, known as the DNA damage response (DDR) pathway, drives onset and progression of this group of disorders, which include Huntington’s disease, myotonic dystrophy and various spinocerebellar ataxias. The company is developing antisense oligonucleotide and small interfering RNA development candidates to precisely knock down key components of the DDR pathway that drive repeat expansion. This approach operates upstream of current approaches in development, targeting the fundamental driver of these diseases. By precisely reducing activity of select DDR targets, the company says its approach is designed to halt onset and progression across a wide range of repeat expansion disorders.